Rep. Jefferson Shreve Sells Off Shares of Repligen Co. (NASDAQ:RGEN)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Repligen Co. NASDAQ: RGEN. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Repligen stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

Repligen Stock Down 3.9%

NASDAQ:RGEN traded down $5.03 on Thursday, hitting $123.01. 117,118 shares of the company's stock traded hands, compared to its average volume of 727,013. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm has a 50-day moving average price of $133.98 and a 200-day moving average price of $145.33. The company has a market cap of $6.91 billion, a PE ratio of -240.59, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 EPS. Equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the subject of several analyst reports. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. JPMorgan Chase & Co. reduced their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Institutional Trading of Repligen

Several large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the period. Point72 Asset Management L.P. lifted its position in Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after purchasing an additional 594,189 shares during the period. Groupama Asset Managment lifted its position in Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after purchasing an additional 400,680 shares during the period. Alyeska Investment Group L.P. acquired a new position in Repligen during the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $52,492,000. Institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In related news, Director Margaret Pax bought 250 shares of the company's stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by corporate insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.